FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550552259> ?p ?o ?g. }

• W2550552259 abstract "Abstract Abstract 3104 Diffuse large B-cell lymphoma (DLBCL) is the most common sub-type of non-Hodgkin's lymphoma.1 DLBCL is a heterogeneous, clinically aggressive disease, which has recently been sub-categorized based upon gene expression profiling. The prognosis of patients with DLBCL is presently assessed by the International Prognostic Index (IPI), which predicts estimated five-year survival based on clinical criteria.1,2 Over the past decade, a number of reports have established that the intra-tumoral content of the phospholipid-related metabolites phosphoethanolamine and phosphocholine (Etn-P and Cho-P) is increased in clinically aggressive malignant disease, and decreases when the malignancy responds to anticancer treatment. These data suggest that phospholipid metabolism is an intrinsic part of the disease process.3,4 Based on these observations, we hypothesized that intra-tumor levels of Etn-P and Cho-P may be a reliable predictive biomarker for therapeutic outcome in aggressive malignant diseases. To test this hypothesis, we measured noninvasively the tumor content of the sum of Etn-P plus Cho-P normalized by the tumor content of nucleoside triphosphates ([Etn-P+Cho-P]/NTP) in patients with DLBCL prior to initiating therapy. These data show that the pretreatment metabolic ratio (PMR) of [Etn-P+Cho-P]/NTP, is a potentially valuable biomarker of outcome, which identifies a subset of DLBCL patients likely to experience early failure to standard therapy, and for whom alternatives to therapy should be considered. Methods: Under ethical review board approval, 27 previously untreated DLBCL patients prior to receiving standard doxorubicin-based therapy were studied noninvasively using 3D localized, 1H-decoupled, nuclear Overhauser-enhanced phosphorus MR spectroscopy at 1.5 T. Result: As only complete response (CR) is clinically meaningful in achieving durable remissions of DLBCL, we divided these patients by response at six months into CR and all the other responses (not complete response, NCR). In the 17 CR patients, the PMR was significantly lower than in the ten NCR patients (PMR mean ± 95% CI, 1.46 ± 0.21 vs. 2.47 ± 0.24, p < 3 × 10-6). The prediction of response using a Fisher test was significant for the PMR alone (p < 1 × 10-4; sensitivity of 1.00, specificity of 0.70) and improved further when combined with the IPI (p < 2 × 10-6; sensitivity of 1.0, specificity of 0.90). The progression-free survival (PFS) strongly correlated with the PMR alone (p < 4 × 10-8) and with the PMR and IPI as covariates (p < 1 × 10-7) by the Cox regression model. Using the Kaplan-Meier model, the PMR discriminated 64% of patients with PFS below 11 months (p < 1 × 10-7), while as covariate with the IPI it discriminated 82% of these patients (p < 2 × 10-7). Discussion: Our results show that the PMR contains information that predicts outcome to standard therapy in DLBCL patients. This prediction improves when the PMR is combined with the IPI. While the PME alone identifies 64% of those patients who will go on to show an extremely poor response with a progression-free survival below 11 months, the combination of the PME and IPI identify 82% of these patients. In conclusion, we have successfully demonstrated that the PMR can be an important determinant in predicting response to treatment in patients with DLBCL, especially when integrated with the IPI. References: 1) Cancer: principles and practice of oncology. 6th ed. Philadelphia, PA, Lippincott, Williams & Wilkins, 2001; 2) Smith MR, Non-Hodgkin's lymphoma. St. Louis, MO, Mosby, 1966; 3) Arias-Mendoza F, Brown TR, Dis. Markers, 2003;19:49-68; 4)Griffiths JR, et al, Lancet 1983;1:1435-6 Disclosures: No relevant conflicts of interest to declare." @default.
• W2550552259 created "2016-11-30" @default.
• W2550552259 creator A5002126535 @default.
• W2550552259 creator A5008227267 @default.
• W2550552259 creator A5012067785 @default.
• W2550552259 creator A5014003098 @default.
• W2550552259 creator A5014841060 @default.
• W2550552259 creator A5035363478 @default.
• W2550552259 creator A5036062833 @default.
• W2550552259 creator A5037497459 @default.
• W2550552259 creator A5045599324 @default.
• W2550552259 creator A5048037390 @default.
• W2550552259 creator A5051999451 @default.
• W2550552259 creator A5059124819 @default.
• W2550552259 creator A5065401076 @default.
• W2550552259 creator A5072699629 @default.
• W2550552259 creator A5075714323 @default.
• W2550552259 creator A5077895949 @default.
• W2550552259 creator A5078379637 @default.
• W2550552259 creator A5080630441 @default.
• W2550552259 creator A5084260960 @default.
• W2550552259 creator A5086875861 @default.
• W2550552259 creator A5089854184 @default.
• W2550552259 date "2010-11-19" @default.
• W2550552259 modified "2023-10-18" @default.
• W2550552259 title "Phosphorus Magnetic Resonance Spectroscopy Predicts Outcome to Chemotherapy In Patients with Diffuse Large B-Cell Lymphoma: A Prospective International Multicenter Analysis of a Pretreatment Metabolic Biomarker of Response" @default.
• W2550552259 doi "https://doi.org/10.1182/blood.v116.21.3104.3104" @default.
• W2550552259 hasPublicationYear "2010" @default.
• W2550552259 type Work @default.
• W2550552259 sameAs 2550552259 @default.
• W2550552259 citedByCount "0" @default.
• W2550552259 crossrefType "journal-article" @default.
• W2550552259 hasAuthorship W2550552259A5002126535 @default.
• W2550552259 hasAuthorship W2550552259A5008227267 @default.
• W2550552259 hasAuthorship W2550552259A5012067785 @default.
• W2550552259 hasAuthorship W2550552259A5014003098 @default.
• W2550552259 hasAuthorship W2550552259A5014841060 @default.
• W2550552259 hasAuthorship W2550552259A5035363478 @default.
• W2550552259 hasAuthorship W2550552259A5036062833 @default.
• W2550552259 hasAuthorship W2550552259A5037497459 @default.
• W2550552259 hasAuthorship W2550552259A5045599324 @default.
• W2550552259 hasAuthorship W2550552259A5048037390 @default.
• W2550552259 hasAuthorship W2550552259A5051999451 @default.
• W2550552259 hasAuthorship W2550552259A5059124819 @default.
• W2550552259 hasAuthorship W2550552259A5065401076 @default.
• W2550552259 hasAuthorship W2550552259A5072699629 @default.
• W2550552259 hasAuthorship W2550552259A5075714323 @default.
• W2550552259 hasAuthorship W2550552259A5077895949 @default.
• W2550552259 hasAuthorship W2550552259A5078379637 @default.
• W2550552259 hasAuthorship W2550552259A5080630441 @default.
• W2550552259 hasAuthorship W2550552259A5084260960 @default.
• W2550552259 hasAuthorship W2550552259A5086875861 @default.
• W2550552259 hasAuthorship W2550552259A5089854184 @default.
• W2550552259 hasConcept C126322002 @default.
• W2550552259 hasConcept C143998085 @default.
• W2550552259 hasConcept C2778476033 @default.
• W2550552259 hasConcept C2778559949 @default.
• W2550552259 hasConcept C2779338263 @default.
• W2550552259 hasConcept C2781197716 @default.
• W2550552259 hasConcept C55493867 @default.
• W2550552259 hasConcept C71924100 @default.
• W2550552259 hasConcept C86803240 @default.
• W2550552259 hasConceptScore W2550552259C126322002 @default.
• W2550552259 hasConceptScore W2550552259C143998085 @default.
• W2550552259 hasConceptScore W2550552259C2778476033 @default.
• W2550552259 hasConceptScore W2550552259C2778559949 @default.
• W2550552259 hasConceptScore W2550552259C2779338263 @default.
• W2550552259 hasConceptScore W2550552259C2781197716 @default.
• W2550552259 hasConceptScore W2550552259C55493867 @default.
• W2550552259 hasConceptScore W2550552259C71924100 @default.
• W2550552259 hasConceptScore W2550552259C86803240 @default.
• W2550552259 hasLocation W25505522591 @default.
• W2550552259 hasOpenAccess W2550552259 @default.
• W2550552259 hasPrimaryLocation W25505522591 @default.
• W2550552259 isParatext "false" @default.
• W2550552259 isRetracted "false" @default.
• W2550552259 magId "2550552259" @default.
• W2550552259 workType "article" @default.